Dr.Steve Gitelman (University of California, San Francisco) had led the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes) which was sponsored by the Immune Tolerance Network (ITN). The results of this study was published today in iThe Lancet Diabetes (and) Endocrinology/i. The study did not meet its primary endpoint: at 12 months, insulin production, as measured by C-peptide responses, showed no difference in overall decline between the treatment ...You have just read an article categorized health
titled Type 1 Diabetes Study Finds No Difference In Overall Decline Between Treatment And Placebo Groups.
Written by:
editor - Wednesday, August 28, 2013
There are currently no comments for "Type 1 Diabetes Study Finds No Difference In Overall Decline Between Treatment And Placebo Groups"
Post a Comment